VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
FATE
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
FATEFate Therapeutics, Inc.
$1.14$133M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksFATEFinancials

Fate Therapeutics, Inc. (FATE) Income Statement

15Y historyFree accessUpdated daily

Revenue has contracted to $2.1M in 2026Q2 from $6.8M in 2024Q2 (~69% decline) on lumpy milestone recognition that swung gross margin between -124.6% (2026Q1) and 100% (2026Q2), while R&D and SG&A cuts of ~30% and ~72% respectively narrowed operating losses to -$31.1M.

Income StatementBalance SheetCash FlowRatios

FATE Income Statement

Annual statement

FATE Income Statement

Fate Therapeutics, Inc. (FATE) annual income statement — 15-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11
Sales/Revenue4.75M6.65M13.63M63.53M96.3M55.85M31.43M10.68M4.74M4.11M4.4M2.43M0971K2.67M1.17M
Revenue Growth %-33.45%-51.24%-78.55%-34.03%72.44%77.66%194.33%125.32%15.44%-6.72%81.08%--100%-63.63%128.21%-
Cost of Goods Sold5.6M12.9M118.53M157.19M13.76M5.85M125.62M056.02M34.36M26.45M19.86M16.43M12.01M12M0
COGS % of Revenue-194.12%869.57%247.41%14.29%10.48%399.64%-1181.94%836.78%600.91%816.99%-1236.56%449.4%-
Gross Profit-846K-6.25M-104.9M-93.65M82.54M50M-94.19M10.68M-51.28M-30.25M-22.05M-17.43M-16.43M-11.04M-9.33M1.17M
Gross Margin %-17.81%-94.12%-769.57%-147.41%85.71%89.52%-299.64%100%-1081.94%-736.78%-500.91%-716.99%--1136.56%-349.4%100%
Gross Profit Growth %-94.04%-12.01%-213.46%65.1%153.08%-981.92%120.83%-69.52%-37.2%-26.51%-6.05%-48.92%-18.3%-897.35%-
Operating Expenses130.26M141.45M105.38M96.86M390.93M266.99M33.9M111.41M71.83M46.23M36.37M30.21M24.9M18.65M16.23M14.46M
OpEx % of Revenue-2128.33%773.06%152.45%405.95%478.08%107.83%1043.14%1515.44%1125.94%826.1%1242.82%-1920.29%607.75%1236.15%
Selling, General & Admin37.12M46.52M90.64M96.86M84.23M57.32M33.9M23.64M15.81M11.87M9.91M10.35M8.47M6.64M4.23M4.61M
SG&A % of Revenue-699.99%664.95%152.45%87.47%102.64%107.83%221.32%333.5%289.16%225.19%425.83%-683.73%158.35%393.59%
Research & Development95.81M107.83M135M172.6M320.45M215.52M125.62M87.77M56.02M34.36M26.45M19.86M16.43M12.01M12M9.86M
R&D % of Revenue-1622.46%990.4%271.66%332.77%385.92%399.64%821.82%1181.94%836.78%600.91%816.99%-1236.56%449.4%842.56%
Other Operating Expenses-1000K-12.9M-120.26M-172.6M-13.76M-5.85M-125.62M000000000
Operating Income-131.1M-147.7M-210.28M-190.51M-308.39M-216.99M-128.09M-100.73M-67.09M-42.13M-31.96M-27.78M-24.9M-17.68M-13.56M-13.29M
Operating Margin %-2760.04%-2222.45%-1542.63%-299.86%-320.23%-388.56%-407.47%-943.14%-1415.44%-1025.94%-726.1%-1142.82%--1820.29%-507.75%-1136.15%
Operating Income Growth %-29.76%-10.37%38.22%-42.12%-69.41%-27.16%-50.13%-59.27%-31.79%-15.05%-11.56%-40.9%-30.38%-1.99%-
EBITDA-119.66M-138.41M-191.31M-172.23M-294.63M-211.14M-125M-98.53M-65.89M-41.15M-31.08M-27.09M-24.41M-17.1M-12.97M-12.62M
EBITDA Margin %-2519.22%-2082.59%-1403.52%-271.09%-305.95%-378.08%-397.65%-922.6%-1390.04%-1002.29%-706.09%-1114.56%--1761.48%-485.66%-1078.72%
EBITDA Growth %25.25%27.65%-11.08%41.54%-39.54%-68.92%-26.86%-49.55%-60.1%-32.4%-14.71%-11.01%-42.7%-31.9%-2.74%-
D&A (Non-Cash Add-back)11.44M9.29M18.96M18.28M13.76M5.85M3.09M2.19M1.2M971K881K687K496K571K590K672K
EBIT-126.24M-136.31M-195.54M-160.93M-281.72M-212.15M-128.09M-96.4M-64.9M-41.68M-31.82M-27.77M-25.33M-20.1M-13.75M-13.3M
Net Interest Income7.05M11.05M17.29M17.19M5.84M1.31M2.4M2.58M494K-709K-1.5M-2.21M-547K-790K-486K-125K
Interest Income7.05M11.05M17.29M17.19M5.84M1.31M2.4M4.33M2.19M559K138K10K2K6K1K2K
Interest Expense00000001.75M1.7M1.27M1.64M2.22M549K796K487K127K
Other Income/Expense6.67M11.39M24.01M29.58M26.66M4.84M-45.3M2.58M494K-827K-1.5M-2.21M-979K-3.22M-682K-134K
Pretax Income-124.43M-136.31M-186.26M-160.93M-281.72M-212.15M-173.39M-98.15M-66.6M-42.95M-33.46M-29.99M-25.88M-20.89M-14.24M-13.43M
Pretax Margin %-2619.64%-2051.08%-1366.46%-253.3%-292.55%-379.89%-551.59%-919%-1405.02%-1046.08%-760.15%-1233.73%--2151.8%-533.3%-1147.61%
Income Tax000000000297K0053K00127K
Effective Tax Rate %0%0%0%0%0%0%0%0%0%-0.69%0%0%-0.2%0%0%-0.95%
Net Income-124.43M-136.31M-186.26M-160.93M-281.72M-212.15M-173.39M-98.15M-66.6M-42.95M-33.46M-29.99M-25.88M-20.89M-14.24M-13.43M
Net Margin %-2619.64%-2051.08%-1366.46%-253.3%-292.55%-379.89%-551.59%-919%-1405.02%-1046.08%-760.15%-1233.73%--2151.8%-533.3%-1147.61%
Net Income Growth %20.28%26.82%-15.74%42.88%-32.79%-22.36%-76.66%-47.38%-55.05%-28.36%-11.57%-15.88%-23.88%-46.74%-6.05%-
Net Income (Continuing)-124.43M-136.31M-186.26M-160.93M-281.72M-212.15M-173.39M-98.15M-66.6M-42.95M-33.46M-29.99M-25.88M-20.89M-14.24M-13.43M
Discontinued Operations0000000000000000
Minority Interest0000000000000000
EPS (Diluted)-1.01-1.15-1.64-1.64-2.91-2.24-2.10-1.43-1.19-1.02-1.05-1.18-1.27-1.06-1.61-1.51
EPS Growth %21.97%29.88%0%43.64%-29.91%-6.67%-46.85%-20.17%-16.67%2.86%11.02%7.09%-19.81%34.16%-6.62%-
EPS (Basic)--1.15-1.64-1.64-2.91-2.24-2.10-1.43-1.19-1.02-1.05-1.18-1.27-1.07-1.61-1.51
Diluted Shares Outstanding123.66M118.79M113.69M98.41M96.83M94.75M82.39M68.19M56.2M41.98M31.75M25.48M20.45M19.75M8.87M8.87M
Basic Shares Outstanding123.66M118.79M113.69M98.41M96.83M94.75M82.39M68.19M56.2M41.98M31.75M25.48M20.45M19.44M8.87M8.87M
Dividend Payout Ratio----------------

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetAdequate
Cash FlowBurning
Top Statement Risk

Revenue sustainability amid losses

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Revenue Base Collapses Under Partnership Volatility

FATE's quarterly revenue has compressed from $6.8M in 2024Q2 to $2.1M in 2026Q2, a ~69% decline driven by lumpy collaboration milestones rather than product sales, rendering top-line trends unreliable indicators of underlying commercial traction according to the company's reported financials.

The revenue stream appears dominated by episodic collaboration or milestone payments rather than recurring product revenue, evidenced by wild swings such as the drop from $3.1M (2024Q3) to $1.7M (2025Q3) and the -96.7% YoY collapse in 2024Q1. This pattern suggests FATE lacks a commercialized product and remains dependent on partnership-triggered payments that may not be predictable or repeatable. Investors should question whether the modest 9.2% uptick in 2026Q2 reflects genuine pipeline momentum or simply a one-time recognition event.

Erratic Gross Margins Signal Misaligned Revenue Recognition

Gross margin oscillated between -124.6% (2026Q1) and 100% (2026Q2), reflecting that manufacturing and cost-of-goods expenses are not aligned with the timing of milestone-based revenue recognition, a structural distortion that makes margin analysis largely meaningless for FATE based on the reported data.

The negative gross profit in quarters like 2025Q3 (-$24.1M) versus the fully-absorbed 100% margins in 2026Q2 and 2025Q4 indicates that COGS — likely manufacturing scale-up and clinical material costs — are being incurred ahead of, or independent of, revenue recognition. This suggests significant operating infrastructure costs are being carried without corresponding commercial output. The company cannot claim meaningful pricing power or margin discipline until it generates product-based revenue where gross margins stabilize.

Aggressive Cost Cuts Narrow Losses Without Growth

R&D spending fell from $34.6M per quarter in 2024 to $24.4M in 2026Q2 (~30% reduction), while SG&A dropped from $31.7M to $8.8M (~72% reduction), cutting operating losses from -$61.7M to -$31.1M according to FATE's quarterly statements.

The bulk of the loss reduction comes from overhead and SG&A discipline rather than R&D retrenchment, suggesting the company protected pipeline investment while eliminating corporate infrastructure — a rational reallocation for a clinical-stage biotech. However, the simultaneous revenue decline means that cost cuts, not commercialization, are doing the heavy lifting on operating margin improvement. The trajectory from -$0.47 EPS (2024Q1) to -$0.25 (2026Q2) appears driven entirely by expense management, which has finite room to deliver further improvement.

SBC Wind-Down Masks Underlying Cash Consumption

Stock-based compensation declined from $11.0M in 2024Q1 to $3.5M in 2026Q2, a 68% reduction that flatters the trajectory of reported net losses, which improved from -$48.0M to -$30.2M over the same period per FATE's income statements.

SBC's contribution to operating expenses has fallen materially, which may indicate reduced equity issuance or reset option pricing rather than a structural shift in compensation philosophy — a distinction that matters for future dilution risk. Stripping out SBC, the underlying operating loss improvement is less dramatic, as a meaningful portion of the 'narrowing' reflects accounting normalization rather than operating efficiency gains. Tax rate and non-operating items show no anomalies, but net losses remain dominated by cash operating expenses, underscoring the gap between GAAP profitability and any near-term path to breakeven.

Cost Discipline Cannot Sustain a Biotech Without Revenue

FATE is burning ~$31M per quarter in operating losses against $2.1M in quarterly revenue (2026Q2), a 15:1 loss-to-revenue ratio that — absent a near-term regulatory or commercial catalyst — implies a finite runway that cost optimization alone cannot extend indefinitely.

The peer set includes companies like Intellia ($67.7M revenue) and Beam ($139.7M) that have materially larger collaboration or product revenue streams, highlighting FATE's relative commercial immaturity despite similar clinical-stage positioning. If the current revenue run-rate of ~$8M annualized persists while operating expenses stabilize at ~$125M/year, the implied cash consumption of $115M+ annually may force dilutive financing well before any product launch. Investors should scrutinize pipeline catalyst timing against remaining liquidity, as continued margin compression on an already negligible revenue base could accelerate the need for capital markets access.

FATE — Frequently Asked Questions

Quick answers to the most common questions about buying FATE stock.

What was Fate Therapeutics, Inc.'s (FATE) revenue in 2025?

For fiscal year 2025, Fate Therapeutics, Inc. (FATE) reported total revenue of $6.6M. This represents a 468.0% increase compared to $1.2M in 2011.

Is Fate Therapeutics, Inc. (FATE) profitable?

Fate Therapeutics, Inc. (FATE) reported a net loss of $136.3M for the fiscal year ending 2025.

What is Fate Therapeutics, Inc.'s operating profit margin?

Fate Therapeutics, Inc. (FATE) reported an operating income of $-147.7M, resulting in an operating profit margin of -2222.4%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Fate Therapeutics, Inc.'s gross profit and gross margin?

Fate Therapeutics, Inc. (FATE) generated $-6.3M in gross profit for the year, representing a gross profit margin of -94.1%. This demonstrates the company's core pricing power and production efficiency.